Evaluation of the Relationship between Prostate Cancer and Serum ?nflammation Markers

authors:

avatar Mustafa Aldemir 1 , * , avatar Kemal Ener 2 , avatar Deniz Dehni 2 , avatar Koray A?ras 2 , avatar nder Kay?gil 2

Department of Urology, Second Urology Clinic, Atatrk Teaching and Research Hospital, drmaldemir@yahoo.com.tr, Turkey
Department of Urology, Second Urology Clinic, Atatrk Teaching and Research Hospital, Turkey

how to cite: Aldemir M, Ener K, Dehni D, A?ras K, Kay?gil N. Evaluation of the Relationship between Prostate Cancer and Serum ?nflammation Markers. Nephro-Urol Mon. 2010;2(1): 244-250. 

Abstract

Background and Aims: In this study, we aimed to examine whether there is a relationship between the serum inflammation markers C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), erythrocyte sedimantation rate (ESR), ceruloplasmin; and stage of prostate cancer (Pca), serum prostate specific antigen (PSA) level and Gleason score in prostate cancer(Pca) patients. 

Methods: Fourtyone patients diagnosed as prostate cancer, and 46 patients forming the control group, and diagnosed as benign prostatic hyperplasia (BPH) were included in this study. The prostate cancer group was divided into subgroups according to the following parameters; PSA ≤20 ng/mL and >20 ng/mL, Gleason scores of ≤6 and >6, and further the cases with and without bone metastasis.

Results: It was detected that serum levels of CRP, ceruloplasmin and ESR were significantly higher in prostate cancer group, compared with the control group (p<0,05). Serum levels of CRP, ceruloplasmin, LDH and ESR were significantly higher in the Pca group with Gleason score of >6 compared with the Pca patients Gleason score ≤6 (p<0.05). Also, CRP, ceruloplasmin, alkaline phosphatase(ALP), LDH and ESR were significantly higher in the patients with PSA>20 ng/mL, compared with the ones with serum PSA levels≤20 ng/mL in the Pca group, as well (p<0.05).

Conclusions: As a result, it is determined that, the serum inflammation markers are significantly higher at the patients with prostate cancer, especially for the ones with higher PSA and Gleason score.

Full Text

Full text is available in PDF